2-amino-6-cyclohexylaminopurine | 7674-43-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-amino-6-cyclohexylaminopurine
• 英文别名: N~6~-cyclohexyl-7H-purine-2,6-diamine；6-N-cyclohexyl-7H-purine-2,6-diamine
• CAS: 7674-43-3
• 化学式: C₁₁H₁₆N₆
• mdl: MFCD18169231
• 分子量: 232.288
• InChiKey: FWZTVJTUAQOYAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  92.5
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-amino-6-cyclohexylaminopurine 、 (E)-bis(POM)-4-hydroxy-but-2-en-1-yl phosphonate 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 1,4-二氧六环 为溶剂， 以50%的产率得到N⁹-(4'-bis(POM)-phosphinylbut-2'-enyl)-2-amino-6-cyclohexylaminopurine
  参考文献：
  名称：

  Synthesis and antiviral evaluation of bis(POM) prodrugs of (E)-[4′-phosphono-but-2′-en-1′-yl]purine nucleosides

  摘要：

  Seventeen hitherto unknown bis(POM) prodrugs of novel (E)-[4'-phosphono-but-2'-en-1'-yl]purine nucleosides were prepared in a straight approach and at good yields. Those compounds were synthesized by the reaction of purine nucleobases directly with the phosphonate synthon 3 bearing POM biolabile groups under Mitsunobu conditions. All obtained compounds were evaluated for their antiviral activities against a large number of DNA and RNA viruses including herpes simplex viruses 1 and 2, varicella zoster virus, Feline herpes virus, human cytomegalovirus, HIV-1 and HIV-2. Among these molecules, some of them exhibit anti-VZV and anti-HIV activity at submicromolar concentrations. This class of compound will be of further interest for lead optimization as anti-infectious agents. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.08.042
• 作为产物：
  描述：

  环己胺 、 2-氨基-6-氯嘌呤 反应 0.02h， 以94%的产率得到2-amino-6-cyclohexylaminopurine
  参考文献：
  名称：

  在聚焦微波辐射下高效合成取代的胞嘧啶和嘌呤

  摘要：

  描述了在聚焦微波辐射下6-氯嘌呤，2-氨基-6-氯嘌呤和5-溴胞嘧啶与各种亲核试剂的快速亲核取代反应。使用这种方法，可以在较短的反应时间内获得高达99％的收率的所需产物。

  DOI：

  10.1016/j.tet.2007.02.124

文献信息

• [EN] NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES<br/>[FR] NOUVEAUX PHOSPHONATES DE NUCLÉOSIDES ACYCLIQUES ANTIVIRAUX
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2012034719A1

  公开（公告）日：2012-03-22

  Compounds of formula (I) wherein A represents a nucleobase or a derivative thereof, n is equal to 0 or 1 and R', R" are carbonic chain, and R10 is hydrogen or a carbonic chain for their use as antiviral agents.

  式(I)中A代表核碱基或其衍生物，n等于0或1，R'、R"为碳链，R10为氢或碳链，用作抗病毒剂。
• Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)
  申请人：CHEN Han-Min

  公开号：US20140303112A1

  公开（公告）日：2014-10-09

  The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.

  本发明涉及一种治疗疾病或病情的方法，该疾病或病情容易通过AMPK激活剂和公式化合物得到改善，这些化合物有助于激活AMP激活蛋白激酶（AMPK），并将这些化合物用于预防或治疗疾病，包括糖尿病前期、2型糖尿病、X综合症、代谢综合征和肥胖症。
• Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity
  作者：Krikor Bijian、Dominik Wernic、Anita K. Nivedha、Jie Su、Felicia Phei Lin Lim、Caitlin E. Miron、Hind Amzil、Nicolas Moitessier、Moulay A. Alaoui-Jamali

  DOI：10.1021/acs.jmedchem.1c01031

  日期：2022.2.24

  Aurora kinases and protein kinase C (PKC) have been shown to be involved in different aspects of cancer progression. To date, no dual Aurora/PKC inhibitor with clinical efficacy and low toxicity is available. Here, we report the identification of compound 2e as a potent small molecule capable of selectively inhibiting Aurora A kinase and PKC isoforms α, β1, β2 and θ. Compound 2e demonstrated significant

  极光激酶和蛋白激酶 C (PKC) 已被证明与癌症进展的不同方面有关。迄今为止，尚无具有临床疗效和低毒性的双重Aurora/PKC抑制剂。在这里，我们报告了化合物2e的鉴定，它是一种有效的小分子，能够选择性地抑制 Aurora A 激酶和 PKC 异构体​​ α、β1、β2 和 θ。化合物2e在体外显着抑制转移性乳腺癌细胞的集落形成能力和体内转移发展。体外激酶筛选和分子模型研究揭示了含硒侧链在2e中的关键作用，其中硒原子被证明可以通过形成额外的相互作用和调节蛋白质动力学来显着提高其选择性和效力。与硫等其他氢键杂原子相比，我们的研究表明，这些硒原子还具有更有利的 PK 特性。
• [EN] PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS DE PURINE ET MÉTHODE POUR LE TRAITEMENT DU CANCER
  申请人：THE ROYAL INST FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV

  公开号：WO2017181285A1

  公开（公告）日：2017-10-26

  The present disclosure relates to novel compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof; wherein R1, R2, Ra, Rb and Rc are as defined herein, pharmaceutical compositions containing same and methods for the treatment of cancer using same.

  本公开涉及一种新的I式化合物，或其药学上可接受的盐或溶剂；其中R1、R2、Ra、Rb和Rc的定义如本文所述，包含该化合物的制药组合物和使用该化合物治疗癌症的方法。
• Purine compounds and method for the treatment of cancer
  申请人：THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY

  公开号：US10711002B2

  公开（公告）日：2020-07-14

  The present disclosure relates to novel compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof; wherein R1, R2, Ra, Rb and Rc are as defined herein, pharmaceutical compositions containing same and methods for the treatment of cancer using same.

  本公开涉及式 I 的新型化合物，或其药学上可接受的盐或溶液；其中 R1、R2、Ra、Rb 和 Rc 如本文所定义；含有该化合物的药物组合物以及使用该化合物治疗癌症的方法。